STOP OVarian CAncer; Implementation of the Opportunistic Salpingectomy in the Netherlands

NCT ID: NCT04470921

Last Updated: 2024-01-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

10000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-01-01

Study Completion Date

2025-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is to optimize implementation of the opportunistic salpingectomy throughout the Netherlands.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The investigators aim to optimize implementation of opportunistic salpingectomy throughout the Netherlands. The investigators will evaluate the implementation by enrolling patients in a database to evaluate healthcare experiences and to register EOC diagnosis and vital status through yearly PALGA (the nationwide network and registry of histopathology and cytopathology in the Netherlands) and municipal administration searches. In addition, the investigators will perform medical record check to assess which percentage of eligible women have been offered OS.

The investigators expect that a decision aid will be a necessary tool for the decision whether women opt for an OS or not, based on their personal values. After development of the tool(s), the investigators will evaluate the implementation process.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Risk Reduction Ovarian Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Choice for Opportunistic Salpingectomy

Women who will undergo a gynaecological surgery in which currently both ovaries and fallopian tubes would be preserved, can opt for an opportunistic salpingectomy.

Opportunistic Salpingectomy

Intervention Type PROCEDURE

An opportunistic salpingectomy refers to removal of the fallopian tubes without the ovaries during (laparoscopic) interventions for benign (gynaecological) disease to reduce the number of ovarian cancer cases.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Opportunistic Salpingectomy

An opportunistic salpingectomy refers to removal of the fallopian tubes without the ovaries during (laparoscopic) interventions for benign (gynaecological) disease to reduce the number of ovarian cancer cases.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age from 30 years
* Undergoing gynaecological surgery in which currently both ovaries and fallopian tubes would be preserved
* Childbearing completed
* Able to understand the written or spoken Dutch language
* Consent for enrolment in database
* Consent for yearly checks of PALGA database and municipal administration

Exclusion Criteria

* Age under 30 years
* Undergoing surgery without residual ovarian tissue
* Child wish
* Unable to understand the written or spoken Dutch language
* Previous bilateral salpingectomy
* Previous bilateral salpingo-oophorectomy
Minimum Eligible Age

30 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Catharina Ziekenhuis Eindhoven

OTHER

Sponsor Role collaborator

Radboud University Medical Center

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Joanne A de Hullu, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

University Medical Center Nijmegen

Jurgen MJ Piek, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Catharina Ziekenhuis Eindhoven

Rosella PM Hermens, PhD

Role: PRINCIPAL_INVESTIGATOR

Scietific Institute for Quality of Healthcare, UMC Nijmegen

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Jeroen Bosch Hospital

's-Hertogenbosch, , Netherlands

Site Status

OLVG

Amsterdam, , Netherlands

Site Status

Academic Medical Centrum

Amsterdam, , Netherlands

Site Status

Rijnstate Hospital

Arnhem, , Netherlands

Site Status

Amphia hospital

Breda, , Netherlands

Site Status

Reinier de Graaf

Delft, , Netherlands

Site Status

Slingeland Hospital

Doetinchem, , Netherlands

Site Status

Albert Schweitzer hospital

Dordrecht, , Netherlands

Site Status

Catharina Hospital

Eindhoven, , Netherlands

Site Status

Medical Spectrum Twente

Enschede, , Netherlands

Site Status

Martini hospital

Groningen, , Netherlands

Site Status

Spaarne Gasthuis

Haarlem, , Netherlands

Site Status

Ziekenhuisgroep Twente

Hengelo, , Netherlands

Site Status

Medical Center Leewarden

Leeuwarden, , Netherlands

Site Status

Leids University Medical Center

Leiden, , Netherlands

Site Status

Maastricht University Medical Center

Maastricht, , Netherlands

Site Status

St Antonius

Nieuwegein, , Netherlands

Site Status

Radboud UMC

Nijmegen, , Netherlands

Site Status

Canisius Wilhelmina Hospital

Nijmegen, , Netherlands

Site Status

Erasmus Medical Center

Rotterdam, , Netherlands

Site Status

Haaglanden Medical Center Westeinde

The Hague, , Netherlands

Site Status

Elisabeth-Tweesteden Hospital

Tilburg, , Netherlands

Site Status

Diakonessenhuis

Utrecht, , Netherlands

Site Status

Maxima Medical Center

Veldhoven, , Netherlands

Site Status

VieCuri Medical Center

Venlo, , Netherlands

Site Status

Sint Jans Gasthuis

Weert, , Netherlands

Site Status

Isala

Zwolle, , Netherlands

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Netherlands

References

Explore related publications, articles, or registry entries linked to this study.

Yoon SH, Kim SN, Shim SH, Kang SB, Lee SJ. Bilateral salpingectomy can reduce the risk of ovarian cancer in the general population: A meta-analysis. Eur J Cancer. 2016 Mar;55:38-46. doi: 10.1016/j.ejca.2015.12.003. Epub 2016 Jan 8.

Reference Type BACKGROUND
PMID: 26773418 (View on PubMed)

Kwon JS, McAlpine JN, Hanley GE, Finlayson SJ, Cohen T, Miller DM, Gilks CB, Huntsman DG. Costs and benefits of opportunistic salpingectomy as an ovarian cancer prevention strategy. Obstet Gynecol. 2015 Feb;125(2):338-345. doi: 10.1097/AOG.0000000000000630.

Reference Type BACKGROUND
PMID: 25568991 (View on PubMed)

van Lieshout LAM, Steenbeek MP, De Hullu JA, Vos MC, Houterman S, Wilkinson J, Piek JM. Hysterectomy with opportunistic salpingectomy versus hysterectomy alone. Cochrane Database Syst Rev. 2019 Aug 28;8(8):CD012858. doi: 10.1002/14651858.CD012858.pub2.

Reference Type BACKGROUND
PMID: 31456223 (View on PubMed)

Steenbeek MP, van Lieshout LAM, Aarts JWM, Piek JMJ, Coppus SFPJ, Massuger LFAG, Hermens RPMG, de Hullu JA. Factors influencing decision-making around opportunistic salpingectomy: a nationwide survey. J Gynecol Oncol. 2019 Jan;30(1):e2. doi: 10.3802/jgo.2019.30.e2. Epub 2018 Apr 30.

Reference Type BACKGROUND
PMID: 30479086 (View on PubMed)

Committee opinion no. 620: Salpingectomy for ovarian cancer prevention. Obstet Gynecol. 2015 Jan;125(1):279-281. doi: 10.1097/01.AOG.0000459871.88564.09.

Reference Type BACKGROUND
PMID: 25560145 (View on PubMed)

Salvador S, Scott S, Francis JA, Agrawal A, Giede C. No. 344-Opportunistic Salpingectomy and Other Methods of Risk Reduction for Ovarian/Fallopian Tube/Peritoneal Cancer in the General Population. J Obstet Gynaecol Can. 2017 Jun;39(6):480-493. doi: 10.1016/j.jogc.2016.12.005.

Reference Type BACKGROUND
PMID: 28527613 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2018-1; 11515

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.